What Mitragyna Speciosa Actually Is, and Why the Extract Form Has Drawn Particular Scrutiny
Mitragyna speciosa is a tropical evergreen tree in the coffee family, native to Southeast Asia, where its leaves have been chewed, brewed, or smoked for several centuries by manual labourers as a stimulant during long workdays and as a folk treatment for various conditions. The plant is more commonly known by its Thai name, kratom. In the last fifteen years, kratom has moved from regional traditional use to a global market driven primarily by online retail in the United States, the United Kingdom, and parts of continental Europe.
The pharmacology is unusual. The leaves contain more than forty alkaloids, of which mitragynine and 7-hydroxymitragynine are the two best characterised. Both interact with mu-opioid receptors in the central nervous system, though through a different binding profile than classical opioids. At low doses, the dominant effect is stimulant-like; at higher doses, the effect shifts toward sedation and analgesia. The U.S. National Institute on Drug Abuse summarises the published research on these mechanisms and notes that the evidence base remains incomplete by the standards typically applied to medications.
Leaf, powder, and extract: why the form matters
Traditional use centres on whole-leaf preparations: chewed fresh, dried and powdered, or brewed as a tea. The alkaloid concentration in dried leaf material is typically 1 to 2 percent by weight, with significant variation by region and harvest.
Mitragyna speciosa extract products concentrate the alkaloids by removing plant matter, producing a material that is several times more potent by weight than the underlying leaf. Extract concentration ratios vary widely between products and producers, which is one of the reasons regulatory bodies have flagged the extract form specifically as a higher-risk preparation.
The U.S. Food and Drug Administration has issued multiple advisories on kratom since 2016, including warnings about contamination (salmonella outbreaks linked to specific products in 2018), inconsistent alkaloid content between batches, and lack of FDA approval for any therapeutic use. The Drug Enforcement Administration has previously moved to schedule kratom as a controlled substance and has not finalised that scheduling, leaving the legal status in the U.S. determined by individual states.
The UK position is different. Mitragyna speciosa was brought under the Psychoactive Substances Act 2016, which prohibits production, supply, and importation for human consumption. Personal possession is not criminalised under that act. Other jurisdictions across the EU vary substantially.
What the published research actually shows
A series of reviews indexed on the U.S. National Library of Medicine’s PubMed platform have examined kratom across pharmacology, pharmacokinetics, harm profile, and patterns of use.
Documented effects in users include stimulant-type effects at low doses, opioid-type analgesia and sedation at higher doses, dependence with chronic use, and withdrawal symptoms on discontinuation that resemble mild opioid withdrawal.
Documented adverse events include hepatotoxicity in some chronic users, seizures in a small number of cases, neonatal abstinence syndrome in infants of mothers who used kratom during pregnancy, and reported deaths in which kratom alkaloids were detected, often in combination with other substances.
The clinical literature does not yet support kratom or its extracts for any specific therapeutic indication. The FDA, the World Health Organization, and the U.S. National Institutes of Health all describe the current evidence base as insufficient to characterise the full risk profile.
Practical guidance for anyone considering use
The same pattern of guidance appears across the major public health authorities. Speak with a clinician before use, particularly for anyone with liver disease, heart conditions, mental health conditions, current substance use disorders, or who is pregnant or breastfeeding. Avoid combining with alcohol, opioids, benzodiazepines, or other central nervous system depressants. Be aware that products in this market are not regulated for purity or alkaloid content, and that extract products in particular vary substantially in potency between brands and batches.
FAQ
Is kratom legal? Legal status varies by jurisdiction. In the United States, federal status is unscheduled but several states have banned it. In the United Kingdom, supply is prohibited under the Psychoactive Substances Act 2016. EU member states vary.
Are kratom extracts more potent than leaf? Yes. Extract products concentrate the active alkaloids and can be several times more potent by weight than the underlying leaf material.
Has kratom been approved by the FDA? No. The FDA has not approved kratom for any therapeutic use and has issued multiple advisories about its risks.
Can kratom cause dependence? Yes. Published clinical literature documents dependence with chronic use and withdrawal symptoms on discontinuation.
This piece is for educational reference only. Anyone considering use should consult a clinician and review the current FDA and NIDA advisories before making any decisions.
